Invivyd (IVVD) Accounts Payables (2020 - 2026)
Invivyd's (IVVD) quarterly Accounts Payables came in at $9.5 million in Q2 2026, down 47.45% on a YoY basis from $18.1 million in Q2 2025, and down 30.98% quarter-over-quarter from $13.7 million in Q4 2025.
Analysis
Invivyd (IVVD) Accounts Payables (2020 - 2026) Analysis & Trends
Invivyd (IVVD) has reported Accounts Payables for 7 consecutive years, with $9.5 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Accounts Payables fell 47.45% year-over-year to $9.5 million; the trailing twelve-month figure through Jun 2026 stood at $9.5 million (down 47.45% YoY), and the FY2025 full-year result was $13.7 million, up 31.55% from the prior year.
- Accounts Payables declined to $9.5 million in Q2 2026 per IVVD's latest filing, from $13.7 million in the prior quarter.
- Across five years, Accounts Payables topped out at $18.7 million in Q1 2022 and bottomed at $1.2 million in Q1 2024.
- Historically, Accounts Payables has averaged $10.8 million across 5 years, with a median of $9.5 million in 2026.
- The sharpest annual moves came in 2024 and 2025: Accounts Payables sank 80.25% in 2024, then surged 648.2% in 2025.
- Over 5 years, Accounts Payables stood at $1.5 million in 2022, then surged by 424.26% to $8.0 million in 2023, then soared by 31.37% to $10.4 million in 2024, then surged by 31.55% to $13.7 million in 2025, then tumbled by 30.98% to $9.5 million in 2026.
- According to Business Quant data, Accounts Payables over the past three periods registered $9.5 million, $13.7 million, and $18.1 million for Q2 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn | 2.87 Bn |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn | 674.00 Mn |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn | 429.50 Mn |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn | 1.16 Bn |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn | 1.52 Bn |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn | 167.00 Mn |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn | 108.02 Mn |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn | 403.90 Mn |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn | 428.93 Mn |
| 10 | Invivyd | 244.65 Mn | 84.57 Mn | 13.01 Mn | 9.49 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 9.49 Mn |
| Dec 31, 2025 | 13.74 Mn |
| Sep 30, 2025 | 18.10 Mn |
| Jun 30, 2025 | 18.05 Mn |
| Mar 31, 2025 | 8.74 Mn |
| Dec 31, 2024 | 10.45 Mn |
| Sep 30, 2024 | 17.71 Mn |
| Jun 30, 2024 | 7.50 Mn |
| Mar 31, 2024 | 1.17 Mn |
| Dec 31, 2023 | 7.95 Mn |
| Sep 30, 2023 | 9.17 Mn |
| Jun 30, 2023 | 4.11 Mn |
| Mar 31, 2023 | 5.91 Mn |
| Dec 31, 2022 | 1.52 Mn |
| Sep 30, 2022 | 16.77 Mn |
| Jun 30, 2022 | 14.23 Mn |
| Mar 31, 2022 | 18.68 Mn |
| Dec 31, 2021 | 5.78 Mn |
| Sep 30, 2021 | 17.56 Mn |
| Jun 30, 2021 | 10.72 Mn |